• Publications
  • Influence
Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview
TLDR
Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients and of similar efficacy to the TCAs and the more recently introduced SSRIs. Expand
Plasma levels of the enantiomers of thioridazine, thioridazine 2‐sulfoxide, thioridazine 2‐sulfone, and thioridazine 5‐sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin
TLDR
Significant correlations between the mephenytoin enantiomeric ratio and concentrations of thioridazine and metabolites suggest that cytochrome P450IIC19 could contribute to the biotransformation of thIORidazine into yet‐unknown metabolites, other than thiorilidazine 2‐SO, thiorIDazine 2-SO2, or thiorodazine 5‐SO. Expand
Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies.
TLDR
The results of this analysis failed to reveal any difference in efficacy between moclobemide and imipramine in any subgroup of hospitalized depressives, including patients in the highest HAM-D severity band and psychotic patients. Expand
Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia.
TLDR
The results showed that the ED group had greater changes in anxiety than the EP group during the drug manipulation phases (anxiety increasing during BDZ withdrawal); there were no group differences in agoraphobic symptoms and no evidence that the outcome of the behavior therapy was significantly affected by concurrent BDZ treatment. Expand
Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale.
TLDR
Responses were, in general, higher on the subscale retarded depression than on agitation/anxiety for both placebo and active drugs and the Global Assessment of Efficacy was analyzed. Expand
Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.
The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a majorExpand
Moclobemide and imipramine in chronic depression (dysthymia): an international double‐blind, placebo‐controlled trial
TLDR
This study demonstrates the efficacy of high dose moclobemide and high dose imipramine against placebo in the treatment of dysthymia and the investigators' final overall assessment of tolerability significantly favoured mociohemide over imipramsine. Expand
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo
TLDR
It is concluded that moclobemide may be the second‐generation antidepressant doctors were waiting for, equally effective as the classical antidepressants but far better tolerated. Expand
Double-blind comparison of moclobemide and tranylcypromine in depression.
TLDR
Both treatments resulted in significant amelioration of depression as determined by all rating instruments, and the tolerability of both drugs was good, although moclobemide appeared to possess a small advantage in this regard. Expand
A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression.
TLDR
In a multicenter study of 78 severely depressed inpatients, the efficacy, onset of efficacy, and tolerability of the reversible monoamine oxidase-A inhibitor moclobemide in combination with thioridazine and placebo were compared with those of moclOBemide plus placebo. Expand
...
1
2
3
...